Micrima Limited - Market Research Report

Company Overview

• Name: Micrima Limited

• Mission: To detect more instances of breast cancer, earlier.

• Founded: The company was spun out from the University of Bristol in 2005.

• Founders: Roy Johnson, Professor Alan Preece, and Professor Ian Craddock.

• Key People:

• Adrian Waller, Chief Executive Officer

• Leigh Cornock, Chief Technical Officer

• Emma Jackson, Clinical Affairs Manager

• Nick Randall, Chairman

• Dr. Nisha Sharma, Chair of Clinical Advisory Board

• Headquarters: Micrima Limited, Two Glass Wharf, Bristol, BS2 0EL

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Developing innovative devices for breast tissue property measurement, notably the Mi~Scan® device.

Products

Mi~Scan®

• Description: Mi~Scan® is an innovative device designed for breast tissue composition analysis using safe, non-ionising radio waves. It is capable of measuring and analyzing breast tissue properties quickly, without the need for breast compression.

• Key Features:

• Uses non-ionising radio waves.

• Provides a BI-RADS breast density score in one minute.

• Can be used in diagnostic and primary care settings.

• Does not require breast compression.

• Can be used frequently, improving detection in dense breast tissues.

• Aimed at improving breast cancer risk assessment for all women.

Recent Developments

Products and Innovations

• Mi~Scan® Clinical Trials: The Mi~Scan® device is currently undergoing clinical trials and is expected to be ready for order in October 2024 in Europe. Shipments will begin following European regulatory approval in early 2025.

• Product Launch: The portable Mi~Scan tissue measurement device is expected to be commercially available from October 2024.

• Commercialization Timeline: First shipments of the Mi~Scan® device are projected for 2025 following CE marking under MDR.

New Partnerships and Initiatives

• Research and Awareness: Micrima is actively engaged in raising awareness about breast density. Research in the UK indicated that 9 in 10 women do not know their breast density.

• Clinical Advisory Board: The board includes notable figures such as Richard Sidebottom from Royal Marsden NHS Trust, providing insights and guiding the device's clinical application.

New Features

• Pre-Imaging Technique Integration: The Mi~Scan® device's density scores can be integrated into existing risk profiling models for earlier and more accurate breast cancer risk assessment.

No new partnerships were explicitly noted, and specific new features for other existing products were not detailed beyond those integrated in the Mi~Scan developments.

Contact Information

• Email: [info@micrima.com](mailto:info@micrima.com)

• Website: [Micrima Limited](http://www.micrima.com)

• Address: Micrima Limited, Two Glass Wharf, Bristol, BS2 0EL

Conclusion

Micrima Limited is a pioneering company in the field of breast imaging technology, with significant advancements aimed at improving early detection of breast cancer. Its key product, the Mi~Scan® device, promises to transform the understanding and medical handling of breast density issues, marking a potential shift in breast cancer diagnostics.